Cathie Wood’s latest investment moves for 2026 focus on early-stage biotech companies, while gradually reducing exposure to consumer tech, diagnostics, and space technology firms.

Cathie Wood, founder and CEO of asset management company ARK Invest, has significantly increased allocation to gene editing and genomics stocks, with major purchases in the US biotech company Beam Therapeutics(BEAM.US). As a pioneer in base editing technology, Beam is developing precise gene therapeutics to correct disease-causing mutations. Disclosures show that ARK’s flagship fund, ARK Innovation ETF(ARKK.US), and the ARK Genomic Revolution ETF(ARKG.US) together have accumulated over 195,000 shares of Beam Therapeutics, making it one of ARK’s most aggressive recent bets.

Continuing its recent strategy, the firm also increased its holdings in Intellia Therapeutics, Inc.(NTLA.US) by about 236,000 shares—this medical company uses CRISPR technology for gene repair, aligning perfectly with ARK’s investment direction. To further reflect ARK’s long-term preference for genomic discovery and precision medical tools, the company also bought over 423,000 shares in sequencing technology supplier Pacific Biosciences of California, Inc.(PACB.US).

ARK spent more than $3 million to purchase 101,000 shares of Twist Bioscience(TWST.US), which specializes in synthetic DNA research and production, with applications in drug development, data storage, and biological research. Simultaneously, ARK increased its position in Personalis(PSNL.US) by 88,000 shares—a company whose ultra-deep DNA sequencing technology can be precisely used in early cancer detection and minimal residual disease monitoring.

In non-medical sectors, the ARK Autonomous Technology & Robotics ETF(ARKQ.US) continued to build its holding in Kodiak AI, Inc.(KDK.US) by adding 61,874 shares. At the same time, the ARK Genomic Revolution ETF(ARKG.US) expanded its exposure to precision medical data platform Tempus AI, Inc. Class A(TEM.US).

On the sell side, ARK is systematically rebalancing some of its holdings in medical and technology sectors. Specifically, the ARK Genomic Revolution ETF(ARKG.US) reduced its holding in RNA-targeted therapy biotech company Ionis Pharmaceuticals, Inc.(IONS.US) by 26,645 shares, while also trimming positions in genetic testing firm Natera, Inc.(NTRA.US) and blood-based cancer genomics specialist Guardant Health(GH.US).

ARK Innovation ETF undertook structural portfolio adjustments, selling over 72,000 shares of streaming and ad-tech platform Roku, Inc. Class A(ROKU.US), and reducing its position in Canadian e-commerce software provider Shopify, Inc. Class A(SHOP.US) by over 29,000 shares. Meanwhile, the ARK Autonomous Technology & Robotics ETF(ARKQ.US) made targeted reductions in Rocket Lab(RKLB.US), a space launch and satellite systems supplier.

Looking back at ARK Invest’s 2025 performance—despite selling over 633,000 shares of Tesla Motors, Inc.(TSLA.US), the company continues to be ARK’s largest holding, and the fund as a whole easily outperformed the major US benchmark indexes with a significant advantage.